Merck Is Finding PD-L1 Testing Is Helping Keytruda
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma reported May 5 that Keytruda is selling at billion-dollar run rate this year.
You may also be interested in...
Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints
Merck's Keytruda gains huge advantage in first-line lung cancer as Bristol's stumble in patients with lower expression of PD-L-1 biomarker raises questions about cut-off levels in trials.
Roche's Oncology Strategy: The Long Game Comes Into Focus
Roche may be behind Merck and Bristol in the PD-L1/PD-1 immune checkpoint inhibitor race, but its patient plans for atezolizumab are starting to demonstrate the power of the company's strategy of combining "comprehensive diagnostics" and a broad pipeline to establish a dominant position in immuno-oncology.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.